AstraZeneca PLC said Monday that Bevespi Aerosphere has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease. The company said the approval by China's National Medical Products Administration was based on positive results from the Phase 3 Pinnacle 4 trial in which Bevespi Aerosphere demonstrated a statistically significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Canadian premier said China mishandled coronavirus, then China sniped back in a big way'A large body of facts and data suggest that China did not play down, obfuscate or cover up the dangers posed by the novel coronavirus when it emerged in the Chinese city of Wuhan,' the Chinese consulate stated.
Lire la suite »
Pompeo warns China over interference with U.S. journalists in Hong KongU.S. Secretary of State Mike Pompeo on Sunday said it had come to his attention that the Chinese government had threatened to interfere with the work of U.S. journalists in Hong Kong, and said any decision impinging on Hong Kong's autonomy could affect the U.S. assessment of Hong Kong's status.
Lire la suite »
China urges food companies to boost supplies on fears of further COVID-19 disruptionChina has asked trading firms and food processors to boost inventories of grains and oilseeds as a possible second wave of coronavirus cases and worsening infection rates elsewhere raise concerns about global supply lines.
Lire la suite »
Pompeo says China poses real 'risk' to US, in new interviewIn yet another push from the federal government to highlight the nefarious nature of Communist China, Secretary of State Mike Pompeo said during a radio interview on Saturday that the country's actions pose a real 'risk' to the safety and security of the United States.
Lire la suite »